2024
Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial intelligence applied to electrocardiographic images for the risk stratification of cancer therapeutics-related cardiac dysfunction. European Heart Journal 2024, 45: ehae666.3190. DOI: 10.1093/eurheartj/ehae666.3190.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionImmune checkpoint inhibitorsGlobal longitudinal strainLeft ventricular systolic dysfunctionNon-Hodgkin's lymphomaCardiac dysfunctionAI-ECGNegative control analysesAssociated with higher incidenceVentricular systolic dysfunctionCohort of patientsRisk stratification strategiesCheckpoint inhibitorsTrastuzumab exposureSystolic dysfunctionRisk stratificationBreast cancerRisk biomarkersSecondary outcomesLongitudinal strainStratification strategiesTrastuzumabPatientsHigher incidenceAnthracyclinesArtificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Oikonomou E, Sangha V, Dhingra L, Aminorroaya A, Coppi A, Krumholz H, Baldassarre L, Khera R. Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images. Circulation Cardiovascular Quality And Outcomes 2024 PMID: 39221857, DOI: 10.1161/circoutcomes.124.011504.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular systolic dysfunctionCardiac dysfunctionBreast cancerNon-Hodgkin lymphoma therapyNon-Hodgkin's lymphomaVentricular systolic dysfunctionAssociated with worse global longitudinal strainRisk stratification strategiesHigh-risk groupMonths post-treatmentPost hoc analysisElectrocardiographic (ECGTrastuzumab exposureLymphoma therapySystolic dysfunctionAI-ECGBefore treatmentRisk biomarkersLongitudinal strainLow riskStratification strategiesHigher incidencePositive screen
2023
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang E, Ky B, Lenihan D, Nohria A, Dani S, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC Heart Failure 2023, 12: 67-78. PMID: 37897456, DOI: 10.1016/j.jchf.2023.08.026.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionSGLT2 inhibitor useGuideline-directed medical therapyHeart failureInhibitor useSGLT2 inhibitorsMedical therapyCardiac dysfunctionAntineoplastic therapyAtrial fibrillation/flutterType 2 diabetes mellitusAcute HF exacerbationCox proportional HRsAcute kidney injuryRenal replacement therapyRetrospective cohort analysisIschemic heart diseaseRisk of cardiomyopathyAggregate patient dataTriNetX Research NetworkProportional HRsCause hospitalizationCause mortalityHF exacerbationKidney injury
2021
Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR)
Ordovas KG, Baldassarre LA, Bucciarelli-Ducci C, Carr J, Fernandes JL, Ferreira VM, Frank L, Mavrogeni S, Ntusi N, Ostenfeld E, Parwani P, Pepe A, Raman SV, Sakuma H, Schulz-Menger J, Sierra-Galan LM, Valente AM, Srichai MB. Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic Resonance (SCMR). Journal Of Cardiovascular Magnetic Resonance 2021, 23: 52. PMID: 33966639, PMCID: PMC8108343, DOI: 10.1186/s12968-021-00746-z.Peer-Reviewed Original ResearchConceptsCardiovascular magnetic resonanceCardiovascular diseaseFemale patientsPosition statementHeart diseaseCancer therapy-related cardiac dysfunctionClinical scenariosStable ischemic heart diseaseUse of CMRAcute coronary syndromeSystemic rheumatic diseasesIschemic heart diseaseBicuspid aortic valveCongenital heart diseaseSpecific clinical scenariosMagnetic resonanceAortic syndromeCoronary syndromePeripartum cardiomyopathyCardiac dysfunctionRheumatic diseasesClinical evidenceAortic valveVascular disordersClinical care
2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils
Baldassarre LA, Yang EH, Cheng RK, DeCara JM, Dent S, Liu JE, Rudski LG, Strom JB, Thavendiranathan P, Barac A, Zaha VG, Bucciarelli-Ducci C, Ellahham S, Deswal A, Lenneman C, Villarraga HR, Blaes AH, Ismail-Khan R, Ky B, Leja MJ, Scherrer-Crosbie M. Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. Journal Of The National Cancer Institute 2020, 113: 513-522. PMID: 33179744, PMCID: PMC7717327, DOI: 10.1093/jnci/djaa177.Peer-Reviewed Original ResearchConceptsCardio-OncologyCardiovascular careCOVID-19Cardio-oncology patientsPrior cancer historyExpert consensus statementCoronavirus disease 2019 (COVID-19) pandemicExpert consensus documentRisk of infectionDisease 2019 pandemicCardiotoxicity surveillanceCardiovascular complicationsPericardial involvementLethal complicationCardiac dysfunctionOncology patientsRisk of exposureCancer historyCancer patientsCardiovascular diseaseConsensus statementAmerican CollegeCardiovascular treatmentConsensus documentPatients